Pharmaguideline, profile picture
Uploaded byPharmaguideline
PPT, PDF25,250 views

Quality Assurance in Pharmaceuticals

The document outlines quality assurance (QA) and quality control (QC) procedures within the pharmaceutical industry, detailing the importance of ensuring products meet required quality standards for their intended use. It discusses various regulatory aspects, including guidelines for impurity and degradation product acceptance, microbiological quality attributes, and the development and maintenance of standard operating procedures. Additionally, it emphasizes the significance of documentation and change control in maintaining compliance and ensuring product safety and efficacy.

Healthcare◦
Related topics:
Quality Assurance•

Embed presentation

Downloaded 548 times
Quality AssuranceQuality Assurance && QualityQuality ControlControl In Pharma IndustryIn Pharma Industry
QC GMP QA
It is the sum total of the organized arrangements with the objective of ensuring that products will be of the quality required for their intended use QA
Is that part of Quality Assurance aimed at ensuring that products are consistently manufactured to a quality appropriate to their intended use GMP
Is that part of GMP concerned with sampling, specification & testing, documentation & release procedures which ensure that the necessary & relevant tests are performed & the product is released for use only after ascertaining it’s quality QC
QAQA andand QCQC • QC is that part of GMP which is concerned with sampling, specifications, testing and with in the organization, documentation,and release procedures which ensure that the necessary and relevant tests are carried out • QA is the sum total of organized arrangements made with the object of ensuring that product will be of the Quality required by their intended use.
QAQA andand QCQC • Operational laboratory techniques and activities used to fulfill the requirement of Quality • All those planned or systematic actions necessary to provide adequate confidence that a product will satisfy the requirements for quality
QAQA andand QCQC • QC is lab based• QA is company based
Determine impurity level in relevant batches1 Acceptance criterion = A or B (as appropriate) Is impurity also a degradation product? Is A or B greater than the qualified level? Acceptance criterion = qualified level or establish new qualified level2 Estimate maximum increase in impurity at retest date using data from relevant accelerated and long-term stability studies Determine maximum likely level as: A + increase in degradation product at appropriate storage conditions. (Let this = B) YES YES NO NO ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE 1 Relevant batches are those from development, pilot and scale-up studies. 2 Refer to ICH Guideline on Impurities in New Drug Substances Definition: upper confidence limit = three times the standard deviation of batch analysis data Determine mean + upper confidence limit for the impurity (Let this = A)
Does degradation occur during product manufacture? Estimate maximum increase in degradation product at shelf life using data from relevant accelerated and long-term stability studies. (Let this = D) Determine maximum likely level as drug substance acceptance criterion2 . ((A or B) + C + D) Is maximum likely level greater than the qualified level? Estimate maximum increase in degradation product during manufacture from relevant batches1 . (Let this = C) Acceptance criterion = maximum likely level. Acceptance criterion = qualified level or establish new qualified level3 or new storage conditions or reduce shelf life. NO NO YES YES ESTABLISHING ACCEPTANCE CRITERION FOR A DEGRADATION PRODUCT IN A NEW DRUG PRODUCT 1 Relevant batches are those from development, pilot and scale-up studies. 2 Refer to Decision Tree 1 for information regarding A and B. 3 Refer to ICH Guideline on Impurities in New Drug Products.
Is the drug product a solid dosage form or liquid containing undissolved drug substance? No drug substance particle size acceptance criterion required for solution dosage forms. 1. Is the particle size critical to dissolution, solubility, or bioavailability? 2. Is the particle size critical to drug product processability? 3. Is the particle size critical to drug product stability? 4. Is the particle size critical to drug product content uniformity? 5. Is particle size critical for maintaining product appearance? Set Acceptance Criterion No Acceptance Criterion Required If YES to any If NO to all NO YES SETTING ACCEPTANCE CRITERIA FOR DRUG SUBSTANCE PARTICLE SIZE DISTRIBUTION
INVESTIGATING THE NEED TO SET ACCEPTANCE CRITERIA FOR POLYMORPHISM IN DRUG SUBSTANCES AND DRUG PRODUCTS Drug Substance 1. 2. NO YES Conduct polymorphism screen on drug substance. No further action Can different polymorphs be formed? GO TO Characterize the forms: e.g., - X-ray Powder Diffraction - DSC / Thermoanalysis - Microscopy - Spectroscopy
INVESTIGATING THE NEED TO SET ACCEPTANCE CRITERIA FOR POLYMORPHISM IN DRUG SUBSTANCES AND DRUG PRODUCTS 2. 3.GO TO NO NO YES Do the forms have different properties? (solubility, stability, melting point) Is drug product safety, performance or efficacy affected? No further test or acceptance criterion for drug substance YES Set acceptance criterion for polymorph content in drug substance
INVESTIGATING THE NEED TO SET ACCEPTANCE CRITERIA FOR POLYMORPHISM IN DRUG SUBSTANCES AND DRUG PRODUCTS 3. YES NO NO YES Does drug product performance testing provide adequate control if polymorph ratio changes (e.g., dissolution)? Establish acceptance criteria for the relevant performance test(s). Monitor polymorph form during stability of drug product. No need to set acceptance criteria for polymorph change in drug product. Does a change occur which could affect safety or efficacy? Establish acceptance criteria which are consistent with safety and/or efficacy. Drug Product - Solid Dosage Form or Liquid Containing Undissolved Drug Substance Undertake the following processes only if technically possible to measure polymorph content in the drug product.
ESTABLISHING IDENTITY, ASSAY AND ENANTIOMERIC IMPURITY PROCEDURES FOR CHIRAL NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS CONTAINING CHIRAL DRUG SUBSTANCES YES AND RACEMIC Consider the need for verifying chiral identity in drug substance release and/or acceptance testing. Is the new drug substance chiral1 ? Chiral identity, assay and impurity procedures are not needed. YES AND ONE ENANTIOMER Needed for drug substance specification:2 -chiral identity3 -chiral assay4 -enantiomeric impurity5 Needed for drug product specification6 : -chiral assay4 -enantiomeric impurity5 NO 1 Chiral substances of natural origin are not addressed in this Guideline. 2 As with other impurities arising in and from raw materials used in drug substance synthesis, control of chiral quality could be established alternatively by applying limits to appropriate starting materials or intermediates when justified from developmental studies. This essentially will be the case when there are multiple chiral centers (e.g., three or more), or when control at a step prior to production of the final drug substance is desirable. 3 A chiral assay or an enantiomeric impurity procedure may be acceptable in lieu of a chiral identity procedure. 4 An achiral assay combined with a method for controlling the opposite enantiomer is acceptable in lieu of a chiral assay. 5 The level of the opposite enantiomer of the drug substance may be derived from chiral assay data or from a separate procedure. 6 Stereospecific testing of drug product may not be necessary if racemization has been demonstrated to be insignificant during drug product manufacture and during storage of the finished dosage form.
MICROBIOLOGICAL QUALITY ATTRIBUTES OF DRUGSMICROBIOLOGICAL QUALITY ATTRIBUTES OF DRUGS SUBSTANCE AND EXCIPIENTSSUBSTANCE AND EXCIPIENTS Is the drug substances/excipient Capable of supporting microbial Growth or viability Is the drug substances/excipient Sterile? Does drug substances/excipient Synthesis/processing involve Steps which inherently Reduce microorganisms? Establish microbial limit acceptance Criteria As per the harmonized pharmacopoeial monograph Are monitoring Microorganism/indicator levels Consistently below acceptance criteria Levels? Test lots on a skip-lot basis for Microbial limits and freedom from Compendial indicator organisms. Test each lot for microbial limits and freedom from compendial indicator organisms. Provide supporting data. Microbial Limits acceptance criteria and testing May not be necessary No further microbial limits testing or Acceptance criteria are necessary Establish microbial limit acceptance criteria As per the harmonized pharmacopeial monograph Does scientific evidence demonstrate that Reducation steps result in microorganism levels <acceptance criteria limits (and the absence of Compendial indicator organisms) In the drug substance/excipient? Provide supporting data. Microbial limits acceptace Criteria and testing May not be necessary YES YES YES YES YES NO NO NO NO NO
1 . What type of drug release acceptance criteria are appropriate? Is the dosage form designed to produce modified release? YES Establish drug release acceptance criteria. Extended release: multiple time points Delayed release: two stages, parallel or sequential Is drug solubility at 37 ± 0.5°C high throughout the physiological pH range? (Dose/ solubility < 250 mL (pH 1.2 - 6.8)) NO Continued on next page. Generally single-point dissolution acceptance criteria with a lower limit are acceptable. Is dosage form dissolution rapid? (Dissolution > 80% in 15 minutes at pH 1.2, 4.0, and 6.8) Has a relationship been determined between disintegration and dissolution? Generally disintegration acceptance criteria with an upper time limit are acceptable. YES NO YES YES NO NO SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION
2. What specific test conditions and acceptance criteria are appropriate? [immediate release] Does dissolution significantly affect bioavailability? (e.g., have relevant developmental batches exhibited unacceptable bioavailability?) Attempt to develop test conditions and acceptance criteria which can distinguish batches with unacceptable bioavailability. YES NO YES NO YES NO Do changes in formulation or manufacturing variables affect dissolution? (Use appropriate ranges. Evaluate dissolution within pH 1.2 - 6.8) Are these changes controlled by another procedure and acceptance criterion? Adopt appropriate test conditions and acceptance criteria without regard to discriminating power, to pass clinically acceptable batches. Adopt test conditions and acceptance criteria which can distinguish these changes. Generally, single point acceptance criteria are acceptable. SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION
3. YES NO NO YES YES NO YES NO Are bioavailability data available for batches with different drug release rates? Is drug release independent of in vitro test conditions? Can an in vitro / in vivo relationship be established? (Modify in vitro test conditions if appropriate.) Use all available stability, clinical, and bioavailability data to establish appropriate acceptance ranges. Use the in vitro / in vivo correlation, along with appropriate batch data, to establish acceptance ranges. Are acceptance ranges >20% of the labeled content? Provide appropriate bioavailability data to validate the acceptance ranges. Finalize acceptance ranges. SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION What are appropriate acceptance ranges? [extended release]
MICROBIOLOGICAL ATTRIBUTES OF NON-STERILEMICROBIOLOGICAL ATTRIBUTES OF NON-STERILE DRUGS PRODUCTSDRUGS PRODUCTS Does the drug product contain Antimicrobial preservatives or possess Inherent antimicrobial activity Is the drug product a dry dosage form (e.g. solid oral or dry powder)? Does scientific evidence demonstrate Growth inhibitory properties of the Drug product? Microbial limits acceptance criteria and testing May not be necessary Establish preservative chemical acceptance criteria and Perform preservative effectiveness validation of product Containing less than or equal to the minimum specifie Preservative concentration, or demonstrate the inherent Antimicrobial activity of the drug product. Establish microbial limit acceptance criteria As per the harmonized pharmacopoeia Monograph. Perform microbial limits testing on a Lot-by-lot basis. Do production lots consistently meet Microbial limits acceptance criteria? Perform skip-lot testing for microbial Limits, or provide scientific justification for no routine microbial limits testing. No No No No YES YES YES YES
Pharmaceuticals Quality Assurance
ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline • Stability Testing of New Drug Substances and Products • Stability Testing: Photostability Testing of New Drug Substances and Products • Stability Testing for New Dosage Forms • Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products • Evaluation for Stability Data • Stability Data Package for Registration Applications in Climatic Zones III and IV • Validation of Analytical Procedures: Text and Methodology • Impurities In New Drug Substances
ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline • Impurities in New Drug Products • Impurities: Guideline for Residual Solvents • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Microbiological Examination of Non-Sterile Products: Microbial Enumerations Tests • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Microbiological Examination of Non-Sterile Products: Test for Specified Micro-Organisms
ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Residue on Ignition/Sulphated Ash • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Extractable Volume of Parenteral Preparations
ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Particulate Contamination: Sub-Visible Particles • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Disintegration • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Uniformity of Dosage Units • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Region on Dissolution Test
ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Sterility Test • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions onTablet Friability • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Polyacrylamide Gel Electrophoresis • Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin
ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline • Quality of Biotechnological Products: Analysis of the Expression Construct in Cells used for Production of r-DNA Derived Protein Products • Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products • Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products • Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process • Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline • Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products • Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients • Pharmaceutical Development • Quality Risk Management • Pharmaceutical Quality System • Quality Implementation Working Group
Quality Assurance (QA) Management Procedure
How to write Standard OperatingHow to write Standard Operating ProcedureProcedure • SOP describes standard SOP format that you can use immediately for your quality procedure. • SOP has instructions on how to write a formal operating procedure for your systems which your people can follow everyday.
All Documents-Classifications,All Documents-Classifications, Definition and Approval MatrixDefinition and Approval Matrix • In this SOP you will find all type of quality and Technical/Master file documents to build up a good quality management system for your manufacturing sites, definition of documents, their classification, approval requirements and retention requirements. • This procedure has schematic diagrams for your understanding of how different types of documents are prepared and stored in a typical documentation.
Quality Documentation ManagementQuality Documentation Management and Change Controland Change Control • This SOP describes how to generate new quality documents or change control of existing documents, review of quality documents, satellite file management, role of document author, approver, document control officer and satellite file administrator. • In this SOP you will also find numbering systems of different quality documents like audit files, SOP’s, forms, manuals, training files, QA agreements, project files etc and their effective archiving system.
Documentation Rule for GMPDocumentation Rule for GMP DocumentsDocuments • This SOP describes the principles to be followed in GMP documents, entry of data and information, signature requirements and correction technique of incorrectly entered data or information.
Quality Documentation-Control,Quality Documentation-Control, Tracking and DistributionTracking and Distribution • In this SOP you will find mainly the role of document control officer during the initiation, creation, circulation and approval of new quality related documents. • It also describes the procedure of modification and review of existing document using a documentation database. • Management of existing and superseded documents is also a art of this procedure. • You will see all the forms referred during the instruction are attached at the end of the procedure.
Preparation, Maintenance andPreparation, Maintenance and Change Control of Master DocumentsChange Control of Master Documents • This SOP particularly focused on the management of master file documents like specifications, control methods, raw materials, finished goods and packaging specification and test reports, formulation, stability files etc required to generate during the product registration in the market. • This SOP gives instruction on their creation, change control, numbering system, approval requirements and maintenance in a simple master file database. • You will see all the forms referred during the instruction are attached at the end of the procedure.
Deviation Report SystemDeviation Report System • It is a regulatory requirement to capture all sorts of deviations evolves in your systems in order to maintain the continuous improvement to your processes and systems. • This SOP describes how to categorize the deviations between production, audit, quality improvements, technical deviations, customer complaints and environmental, health and safety deviations. • It describes the management responsibilities of initiating deviation, capture data, analysis, investigation, determination of assignable causes, generation of management report and initiatives to be taken on corrective and preventative actions.
Shelf Life of ProductShelf Life of Product • This simple SOP describes the meaning of shelf life and provides on how to interpret shelf lives and storage conditions for your raw materials from the Certificate of Analysis, determining expiry date for your finished products by use of raw material date of manufacturing and their shelf lives.
Vendor Selection and EvaluationVendor Selection and Evaluation • This SOP describes the procedure to be followed during the vendor assessment and vendor evaluation for purchasing of raw materials, critical and non critical packaging components, laboratory supplies, engineering supplies and imported finished goods from the vendor. • These instructions are essential for approving prospective vendor.
Vendor CertificationVendor Certification • This procedure aim to describe the process by which a vendor may be certified to supply materials or services. • This procedure applies to vendors that supply a material or service to be used at any stage of manufacture by operations. • Here you will get the roles of each department in the process to certify an approved vendor.
Product Complaint ProcedureProduct Complaint Procedure • This procedure covers the receipt, logging, evaluation, investigation and reporting system of all complaints received from customers for the marketed products. • This SOP contains step by step instruction to be followed in the customer complaint management like numbering of complaint, registration, evaluation of complaints, determination of assignable cause for the complaint deviation, implementation of corrective and preventive actions, trending of complaints and handling of counterfeit products.
Annual Product ReviewAnnual Product Review • This procedure provides a guideline to annual product review which is required to be performed for each product produced for the commercial market to evaluate data, trends and to identify any preventative or corrective action that would lead to product quality improvements and report them to management.
Rework ProcedureRework Procedure • This SOP contains the step by step instruction to be followed when the rework of an in-process or completed finished good is required. • This SOP covers the reworks of in-process manufactured goods where new batch number is introduced for the reworked part and rework of manufactured finished good keeping the same batch number. • This SOP also describes how to create rework protocols for each individual case.
Authorized PersonAuthorized Person • This simple procedure describes the accreditation, accountabilities and responsibilities of an Authorized person, responsible for release of finished goods for sale.
Product Identification andProduct Identification and TraceabilityTraceability • The purpose of this SOP is to define the method used for the identification of all contributing materials that could affect product quality and to ensure their full traceability. • Here you will find instruction on all the records and documents used for the identification and traceability of incoming raw materials and out going finished goods.
AuditsAudits • This SOP describes the process of planning, performing, reporting and follow-up of different audits for your systems like Internal Quality audit, Vendor audit, Environmental Health and Safety (EHS) audit, EHS workplace inspection, Housekeeping audit. • This SOP also describes the process to be followed by manufacturing personnel during an audit from a Regulatory authority.
Example-Checklist for Batch DocumentationExample-Checklist for Batch Documentation • This SOP describes the identification of all documentation relevant to a production process in the form of “Batch Documentation Checklists” and to ensure their collection by completion of the checklists by Authorized Persons. • This procedure is based on an example of tablet packaging process described in the ‘Manufacturing’ category.
Evaluation of Batch DocumentationEvaluation of Batch Documentation and Release for Saleand Release for Sale • This procedure describes the process of collection, evaluation and record of batch related document generated during the production of a batch before an authorized person can release the batch for sale. • This procedure is based on an example of tablet packaging process described in the ‘Manufacturing’ category.
GMP TrainingGMP Training • This SOP describes how to design and deliver GMP related training for your manufacturing staffs, training assessment design, recording of assessment and preparation of training reports.
How to Write Training MaterialsHow to Write Training Materials • This simple SOP contains instructions on how to write training materials, identification of training requirements, available resources, preparation of training aid checklists for your manufacturing staffs.
House Keeping Audit ProcedureHouse Keeping Audit Procedure • This SOP describes the requirements, checklists and reporting procedure on housekeeping audits. • Individual checklist forms are attached at end of the procedure for different areas like process, laboratory, engineering stores, warehouses. • This procedure also describes the handling of non-compliance found during the housekeeping audits.
Management and Control of Contract WorkManagement and Control of Contract Work • The procedure describes the management and control of contract work provided by the contractors for packaging and finished products for your company as well as control of contract works done by your company on behalf of others.
Criteria for Sourcing of RM, CriticalCriteria for Sourcing of RM, Critical Packaging Components and ImportedPackaging Components and Imported Finishing GoodsFinishing Goods • The purpose of this SOP is to describe the process for approval of an external vendor/manufacturer supplying products to your company. • It covers raw materials (including bulk products for subsidiaries and contract manufacturers), critical packaging components in contact with product and imported finished goods. • The SOP also references affiliated documentation detailing the scope of active materials used and the approved manufacturers of these materials.
Quality Concern InvestigationQuality Concern Investigation ProcessProcess • This procedure contains instruction to be followed when conducting Investigations and to raise and assess Deviation Report when an investigation or incident Investigation occurs. • This procedure is to be used in conjunction with SOP, which covers the approval and follow-up activities associated with a Deviation Report. • Here you will find collection of information for an incident or a deviation, steps to be followed for a cross functional investigation, reporting and implementing of the outcomes of investigation.
Quality Control Laboratory Procedures
Retest Dating of Raw MaterialsRetest Dating of Raw Materials • The purpose of this procedure is to describe how to run the expired stock report; to describe how to define the requirements for the retesting and assignment of storage period for active ingredients, excipients and raw materials; to instruct retesting procedure and to determine the status of a finished goods batch with a shorter shelf life.
Calibration Policies for LaboratoryCalibration Policies for Laboratory InstrumentsInstruments • This SOP describes the calibration polices of laboratory instruments/equipments. • It describes labeling and security requirements of laboratory instruments/equipments. • This SOP also describes the investigational steps to be required in the case of failed calibration
Archiving Laboratory DocumentationArchiving Laboratory Documentation • This procedure describes retention and disposal procedures of laboratory documentation, general laboratory documentation system that includes handling of rejected raw material and finished product reports, finished goods certificate of analysis, finished goods register, raw material certificate of analysis, register, trend cards, procedure for long term document retention.
Management of ReferenceManagement of Reference SubstancesSubstances • This SOP describes the ordering referencing, storing, coding, use and general register maintenance of primary and impurity reference substances, primary reagent reference solutions, secondary raw material reference substance, assay testing procedure of secondary raw material reference substance, use of secondary raw material reference substance in the laboratory routine analysis, determination of expiry date and re-test date of reference substances.
Laboratory WorkbookLaboratory Workbook • This SOP describes types of laboratory workbooks, general and GMP requirements of using workbooks, analytical data entry in the workbook, formatting of laboratory workbooks for routine testing, experiments and trials, workbook retention policy, instruction on data entry for incomplete experiments and additional data.
Creation of Certificate of AnalysisCreation of Certificate of Analysis • The purpose of this procedure is to define the content and format of a Certificate of Analysis (C/A) and Certificate of Manufacture (C/M) and to provide guidance for issuing a Certificate of Analysis or Certificate of Manufacture and to locate the appropriate data required for this task.
Managing Analytical ReagentsManaging Analytical Reagents • This procedure identifies the need for all analytical reagents and solutions prepared from the reagents, to have an assigned expiry date and storage conditions recorded on the label. • Here you will find the procedure for purchase and management of analytical reagents and laboratory prepared reagents.
Laboratory Waste ManagementLaboratory Waste Management • This simple procedure describes how to dispose off laboratory generated wastes of toxic, explosive, flammable, corrosive, oxidizing and biologically damaging natures.
Retention Samples-LaboratoryRetention Samples-Laboratory • The purpose of this SOP is to describe the finished good and raw material sample retention procedures, products manufacture and/or received onsite and/or chemically tested by the laboratory.
Laboratory Supplier ApprovalLaboratory Supplier Approval • In this simple SOP you will find the procedure for approving laboratory suppliers and criteria for the purchase of equipment, instrumentation, consumables, durables and glassware for the laboratory.
Laboratory Results-Out of SpecificationLaboratory Results-Out of Specification InvestigationInvestigation • This procedure describes the actions to be taken by an analyst in the event the result of a test does not conform to raw material/components or finished products specifications for physical and chemical tests. • An out of specification (OOS) result does not necessarily mean the batch under investigation fails and shall be rejected. • The OOS result shall be investigated and the findings of the investigation, including re-test results shall be interpreted to evaluate the batch and reach a decision regarding release or rejection.
Raw Materials-Laboratory TestingRaw Materials-Laboratory Testing and Documentationand Documentation • This SOP describes the procedure for sampling, location, pre-testing, testing and documentation of all raw materials and components subject to test, out of specification results, microbiological tests and release procedure for passed raw materials and components.
Finished Goods-Laboratory Testing andFinished Goods-Laboratory Testing and DocumentationDocumentation • This SOP describes the procedure for sampling, location, pre-testing, testing and documentation of all finished products subject to test, reagents and standards to be used for analysis, management of out of specification results, microbiological tests and release procedure for passed finished goods.
Preparation and Maintenance ofPreparation and Maintenance of Stability Protocols (Pharmaceuticals)Stability Protocols (Pharmaceuticals) • This procedure describes the preparation and management of stability protocols for marketed products. • This procedure is applicable to all protocols for stability studies on commercial products. • The responsibility of the commercial Site stability manager for creating and maintaining protocols that are required for studies that came as a result of validation or process deviation.
Stability and Trial Testing ProcedureStability and Trial Testing Procedure (Pharmaceuticals)(Pharmaceuticals) • To describes the steps necessary to ensure the effective control of stability and trial testing programs of new and existing products. • This procedure is focused on setting up of stability programs, testing, reporting, general sampling procedure for stability programs, data generation and analysis, annual maintenance of stability, new product stability procedure, procedure for in-house trials, reporting and interpretation of trials and conclusion of the trail program.
REFERENCESREFERENCES • www.ich.org • www.fda.gov
Pharmaceuticals Quality Assurance

More Related Content

PPTX
Role of quality assurance in pharmaceutical industry
byMuhammad Zubair
 
PDF
THE ROLE OF QA IN PHARMACEUTICALS
byKostas Skopelitis
 
PPTX
QUALITY ASSURANCE
byPharmaceutical
 
PDF
Lecture 2: QA and Qc in Pharma Industry
bySapan Shah
 
PPTX
Pharmaceutical Quality System
byGMP EDUCATION : Not for Profit Organization
 
PPTX
Finished product release, quality review, quality audit and batch release d...
byswrk
 
PPTX
Quality control in pharmaceutical laboratories
bySagar Kamble
 
PPTX
Pharmaceutical Quality System
byAnkur Saikia
 
Role of quality assurance in pharmaceutical industry
byMuhammad Zubair
 
THE ROLE OF QA IN PHARMACEUTICALS
byKostas Skopelitis
 
QUALITY ASSURANCE
byPharmaceutical
 
Lecture 2: QA and Qc in Pharma Industry
bySapan Shah
 
Pharmaceutical Quality System
byGMP EDUCATION : Not for Profit Organization
 
Finished product release, quality review, quality audit and batch release d...
byswrk
 
Quality control in pharmaceutical laboratories
bySagar Kamble
 
Pharmaceutical Quality System
byAnkur Saikia
 

What's hot

PPTX
Q6 guidelines
byAnjali Aji
 
PPTX
Pharmaceutical development report (pdr)
byAtul Bhombe
 
PPTX
Quality management systems
byAudumbar Mali
 
PPTX
PHARMACEUTICAL CALIBRATION, QUALIFICATION AND VALIDATION: AN INTRODUCTION
byPrincy Agarwal
 
PPT
analytical method validation
byDr. Raja Abhilash
 
PPTX
Ich guideline for stability testing
byShubham Gore
 
PPTX
Process validation
bySaravanan subramaniyam
 
PPTX
Ipqc
byPOURNIMA BHALEKAR
 
PPTX
Ich – quality guidelines
byHarishankar Sahu
 
PPTX
Out of specification shravan
byshravan dubey
 
PPTX
WHO GMP Requirements
byDeekshitha HS
 
PPTX
EQUIPMENT VALIDATION.pptx
bySwatiSwagatika6
 
PPTX
Pharmaceutical documentation
byK V NANDA KUMAR
 
PPTX
Cleaning validation
byVinay Jain
 
PPTX
Pharmaceutical Quality Management System
byDhawal_Raghuvanshi
 
PPTX
Pharmaceutical Quality Management System
bySyed Muhammad Danish
 
PPTX
Qualification
byVivek Jain
 
PPTX
Distribution records
byJyotiMhoprekar
 
PPTX
Out of specification (oos)1
byDr. Ravi Kinhikar
 
PPT
Principle of Validation and Qualification
byPharmaguideline
 
Q6 guidelines
byAnjali Aji
 
Pharmaceutical development report (pdr)
byAtul Bhombe
 
Quality management systems
byAudumbar Mali
 
PHARMACEUTICAL CALIBRATION, QUALIFICATION AND VALIDATION: AN INTRODUCTION
byPrincy Agarwal
 
analytical method validation
byDr. Raja Abhilash
 
Ich guideline for stability testing
byShubham Gore
 
Process validation
bySaravanan subramaniyam
 
Ipqc
byPOURNIMA BHALEKAR
 
Ich – quality guidelines
byHarishankar Sahu
 
Out of specification shravan
byshravan dubey
 
WHO GMP Requirements
byDeekshitha HS
 
EQUIPMENT VALIDATION.pptx
bySwatiSwagatika6
 
Pharmaceutical documentation
byK V NANDA KUMAR
 
Cleaning validation
byVinay Jain
 
Pharmaceutical Quality Management System
byDhawal_Raghuvanshi
 
Pharmaceutical Quality Management System
bySyed Muhammad Danish
 
Qualification
byVivek Jain
 
Distribution records
byJyotiMhoprekar
 
Out of specification (oos)1
byDr. Ravi Kinhikar
 
Principle of Validation and Qualification
byPharmaguideline
 

Viewers also liked

PDF
Quality control of pharmaceutical products
bySiham Abdallaha
 
PPT
Quality assurance and regulatory compliance for pharmaceutical product
byProf. Dr. Basavaraj Nanjwade
 
PDF
Pharma regulatory affairs
byGirish Swami
 
PPT
Qa quality assurance
byNavneeth Krishna
 
PPTX
HPLC - High Performance Liquid Chromatography
byDivya Basuti
 
PPTX
Role of quality by design (qb d) in quality assurance of pharmaceutical product
byNitin Patel
 
PPT
Pharmacology
byPrajakta Shinde
 
PPT
1 Quality Assurance Presentation
byguest337c19
 
PDF
Pharma quality assurance and control
byRafat Abedi (IGMPI)
 
PPTX
Quality assurance
byHareesh Sasidharan
 
PPTX
Quality control and quality assurance
byLeola Ramirez
 
PPTX
Validation of sterilization methods
byhimalayan pharmacy institute
 
PPT
Industry Program In Pharma Quality Assurance And Quality Control
bybiinoida
 
PPT
Quality Control
byvishakeb
 
PPTX
Quality control checks in Pharmaceutical industries
byNiranjan139
 
PDF
Microbiologist
byTaher Qasim
 
PPTX
Pharma regulatory and quality assurance
bySachin Bhalekar
 
DOCX
Resume for Microbiologist
bySaloni Jadhav
 
DOC
Microbiology Resume
byWilliam Parker
 
PPT
Session 3 part 5
byplmiami
 
Quality control of pharmaceutical products
bySiham Abdallaha
 
Quality assurance and regulatory compliance for pharmaceutical product
byProf. Dr. Basavaraj Nanjwade
 
Pharma regulatory affairs
byGirish Swami
 
Qa quality assurance
byNavneeth Krishna
 
HPLC - High Performance Liquid Chromatography
byDivya Basuti
 
Role of quality by design (qb d) in quality assurance of pharmaceutical product
byNitin Patel
 
Pharmacology
byPrajakta Shinde
 
1 Quality Assurance Presentation
byguest337c19
 
Pharma quality assurance and control
byRafat Abedi (IGMPI)
 
Quality assurance
byHareesh Sasidharan
 
Quality control and quality assurance
byLeola Ramirez
 
Validation of sterilization methods
byhimalayan pharmacy institute
 
Industry Program In Pharma Quality Assurance And Quality Control
bybiinoida
 
Quality Control
byvishakeb
 
Quality control checks in Pharmaceutical industries
byNiranjan139
 
Microbiologist
byTaher Qasim
 
Pharma regulatory and quality assurance
bySachin Bhalekar
 
Resume for Microbiologist
bySaloni Jadhav
 
Microbiology Resume
byWilliam Parker
 
Session 3 part 5
byplmiami
 

Similar to Quality Assurance in Pharmaceuticals

PPTX
Developing Specification (ICH Q6 and Q3), Purchase specifications and mainten...
bysamkhan166
 
PPTX
Developing specifications q3 q6
byNamrataBawaskar
 
PPTX
ICH Q6A Specifications by Chandra Mohan
byChandra Mohan
 
PDF
special emphasis on Q series guidelines
bysrikrupa institute of pharmaceutical analysis
 
PPTX
Ich Guidelines Au. Vivek Jain
byVivek Jain
 
PPTX
Documentation in pharmaceutical industry
byGayatriTiwaskar
 
PPTX
ICH Q6A & ICH Q7
byMaulik Malvania
 
PPTX
ICH Q8 " PHARMACEUTICAL DEVELOPMENT"
byTalha Mahmood
 
PPTX
Chanduppt2
bychandu chatla
 
PPTX
analsis1.pptx
byMekuanentTerefe1
 
PPTX
ICH Q8
byTalha Mahmood
 
PDF
Analytical method validation workshop
bySiham Abdallaha
 
PPTX
Quality by-design in pharmaceutical development
byritu mishra
 
PDF
1.3 ICH .pdf
byKoriyaKrupali1
 
PPTX
Raw material validation- process validation
byRavish Yadav
 
PPTX
amv ppt.pptx
byAjaySingh22603
 
PDF
Introduction to Pharmaceutical Analysis.pdf
bymollatsegaye27
 
PPT
Monograph changes
byBhaswat Chakraborty
 
PPT
Pharma Specification WHO Quality Worksho
byRajakumari Rajendran
 
PPT
Qualityassurancecontrolinpharmaindustry
byMalla Reddy College of Pharmacy
 
Developing Specification (ICH Q6 and Q3), Purchase specifications and mainten...
bysamkhan166
 
Developing specifications q3 q6
byNamrataBawaskar
 
ICH Q6A Specifications by Chandra Mohan
byChandra Mohan
 
special emphasis on Q series guidelines
bysrikrupa institute of pharmaceutical analysis
 
Ich Guidelines Au. Vivek Jain
byVivek Jain
 
Documentation in pharmaceutical industry
byGayatriTiwaskar
 
ICH Q6A & ICH Q7
byMaulik Malvania
 
ICH Q8 " PHARMACEUTICAL DEVELOPMENT"
byTalha Mahmood
 
Chanduppt2
bychandu chatla
 
analsis1.pptx
byMekuanentTerefe1
 
ICH Q8
byTalha Mahmood
 
Analytical method validation workshop
bySiham Abdallaha
 
Quality by-design in pharmaceutical development
byritu mishra
 
1.3 ICH .pdf
byKoriyaKrupali1
 
Raw material validation- process validation
byRavish Yadav
 
amv ppt.pptx
byAjaySingh22603
 
Introduction to Pharmaceutical Analysis.pdf
bymollatsegaye27
 
Monograph changes
byBhaswat Chakraborty
 
Pharma Specification WHO Quality Worksho
byRajakumari Rajendran
 
Qualityassurancecontrolinpharmaindustry
byMalla Reddy College of Pharmacy
 

More from Pharmaguideline

PPT
Dissolution Testing in Pharmaceuticals
byPharmaguideline
 
PPT
Bacterial Endotoxin Test
byPharmaguideline
 
PPT
Purified Water System in Pharmaceuticals
byPharmaguideline
 
PPT
Cleaning Validation in Pharmaceuticals
byPharmaguideline
 
PDF
Q4 b step4
byPharmaguideline
 
PPT
What is FDA?
byPharmaguideline
 
PPT
Principle of GC and HPLC
byPharmaguideline
 
PDF
Q5 c step4
byPharmaguideline
 
PDF
Q6 b step4
byPharmaguideline
 
PDF
Q5 e step4
byPharmaguideline
 
PDF
Q9 step4
byPharmaguideline
 
PDF
Q5 d step4
byPharmaguideline
 
PDF
Q4 b annex4c r1_ step4
byPharmaguideline
 
PDF
Q4 b annex 13 step 2
byPharmaguideline
 
PDF
Q4 b annex4b r1_ step4
byPharmaguideline
 
PDF
Q4 b annex4a r1_ step4
byPharmaguideline
 
PDF
Q4 b annex 12 step 4
byPharmaguideline
 
PDF
Q5 b step4
byPharmaguideline
 
PDF
Q4 b annex 14 step 2
byPharmaguideline
 
PDF
Q5 a r1_ step4
byPharmaguideline
 
Dissolution Testing in Pharmaceuticals
byPharmaguideline
 
Bacterial Endotoxin Test
byPharmaguideline
 
Purified Water System in Pharmaceuticals
byPharmaguideline
 
Cleaning Validation in Pharmaceuticals
byPharmaguideline
 
Q4 b step4
byPharmaguideline
 
What is FDA?
byPharmaguideline
 
Principle of GC and HPLC
byPharmaguideline
 
Q5 c step4
byPharmaguideline
 
Q6 b step4
byPharmaguideline
 
Q5 e step4
byPharmaguideline
 
Q9 step4
byPharmaguideline
 
Q5 d step4
byPharmaguideline
 
Q4 b annex4c r1_ step4
byPharmaguideline
 
Q4 b annex 13 step 2
byPharmaguideline
 
Q4 b annex4b r1_ step4
byPharmaguideline
 
Q4 b annex4a r1_ step4
byPharmaguideline
 
Q4 b annex 12 step 4
byPharmaguideline
 
Q5 b step4
byPharmaguideline
 
Q4 b annex 14 step 2
byPharmaguideline
 
Q5 a r1_ step4
byPharmaguideline
 

Recently uploaded

PDF
Christmas Cooking Feast/Christmas Cooking Feast
byLahcen Idar
 
PDF
Marc Wanis - A Pre-Medical Scholar
byMarc Wanis
 
PDF
Ariana Lyons: This longitudinal analysis, authored by Ariana Lyons, examines ...
byAriana Lyons
 
PPTX
Spondylosis Physiotherapy, Aayushi Bodiwala
byAayushiBodiwala
 
PPTX
"occupational hazards-physical hazards".
byNishadTaskeen
 
PPT
Introduction to Medicinal Chemistry and data therin
byChatgptgoa
 
PDF
Hospital Administration Software Enhancing Governance, Compliance, and Operat...
byGrapes Innovative Solutions
 
PDF
N8N Automation for Healthcare: Smarter Patient Intake & Scheduling in 2026.
byVirtual Nexgen Solutions
 
DOCX
From Stamping Out to System Control: Transmission Route Neutralisation
byHarm Kiezebrink
 
PDF
Pediatrics in Gastonia helps parents spot sprain versus fracture
byGastonia Pediatric Associates
 
PPTX
Feng_2023_Journal_Club_Presentation.pptx
byishitasingh0610
 
PDF
3 Diabetes complications €& »?!!&&&&.pdf
byy2dyjdrrjk
 
PDF
Bsc nursing syllabus and subject details.pdf
bypavitra8057
 
PPTX
Ante partum hemorrhage- Etiology, diagnosis and management
byDrAkashGajjar
 
PPTX
Liver - spleen - Pancreas- biliary surgery presentation for nurses
byShacharLaks1
 
PPTX
unit 02 urinary system.by zahid abbasi.pptx
byzahidali446434
 
PPTX
Dimensions of health and its vairous aspects
byBhusanThombare
 
PDF
SPA_L3 Core Glossary_2021.pdf healthcare
byaliciaquijanotorres1
 
PPTX
Sudha kalpa sthana charaka samhita .pptx
bydevi7ka
 
PDF
Common Eye Diseases and Symptoms - Dr. Chameen Sams Australia
byDr Chameen Samarawickrama
 
Christmas Cooking Feast/Christmas Cooking Feast
byLahcen Idar
 
Marc Wanis - A Pre-Medical Scholar
byMarc Wanis
 
Ariana Lyons: This longitudinal analysis, authored by Ariana Lyons, examines ...
byAriana Lyons
 
Spondylosis Physiotherapy, Aayushi Bodiwala
byAayushiBodiwala
 
"occupational hazards-physical hazards".
byNishadTaskeen
 
Introduction to Medicinal Chemistry and data therin
byChatgptgoa
 
Hospital Administration Software Enhancing Governance, Compliance, and Operat...
byGrapes Innovative Solutions
 
N8N Automation for Healthcare: Smarter Patient Intake & Scheduling in 2026.
byVirtual Nexgen Solutions
 
From Stamping Out to System Control: Transmission Route Neutralisation
byHarm Kiezebrink
 
Pediatrics in Gastonia helps parents spot sprain versus fracture
byGastonia Pediatric Associates
 
Feng_2023_Journal_Club_Presentation.pptx
byishitasingh0610
 
3 Diabetes complications €& »?!!&&&&.pdf
byy2dyjdrrjk
 
Bsc nursing syllabus and subject details.pdf
bypavitra8057
 
Ante partum hemorrhage- Etiology, diagnosis and management
byDrAkashGajjar
 
Liver - spleen - Pancreas- biliary surgery presentation for nurses
byShacharLaks1
 
unit 02 urinary system.by zahid abbasi.pptx
byzahidali446434
 
Dimensions of health and its vairous aspects
byBhusanThombare
 
SPA_L3 Core Glossary_2021.pdf healthcare
byaliciaquijanotorres1
 
Sudha kalpa sthana charaka samhita .pptx
bydevi7ka
 
Common Eye Diseases and Symptoms - Dr. Chameen Sams Australia
byDr Chameen Samarawickrama
 

Quality Assurance in Pharmaceuticals

  • 1.
    Quality AssuranceQuality Assurance&& QualityQuality ControlControl In Pharma IndustryIn Pharma Industry
  • 2.
  • 3.
    It is thesum total of the organized arrangements with the objective of ensuring that products will be of the quality required for their intended use QA
  • 4.
    Is that partof Quality Assurance aimed at ensuring that products are consistently manufactured to a quality appropriate to their intended use GMP
  • 5.
    Is that partof GMP concerned with sampling, specification & testing, documentation & release procedures which ensure that the necessary & relevant tests are performed & the product is released for use only after ascertaining it’s quality QC
  • 6.
    QAQA andand QCQC •QC is that part of GMP which is concerned with sampling, specifications, testing and with in the organization, documentation,and release procedures which ensure that the necessary and relevant tests are carried out • QA is the sum total of organized arrangements made with the object of ensuring that product will be of the Quality required by their intended use.
  • 7.
    QAQA andand QCQC •Operational laboratory techniques and activities used to fulfill the requirement of Quality • All those planned or systematic actions necessary to provide adequate confidence that a product will satisfy the requirements for quality
  • 8.
    QAQA andand QCQC •QC is lab based• QA is company based
  • 9.
    Determine impurity levelin relevant batches1 Acceptance criterion = A or B (as appropriate) Is impurity also a degradation product? Is A or B greater than the qualified level? Acceptance criterion = qualified level or establish new qualified level2 Estimate maximum increase in impurity at retest date using data from relevant accelerated and long-term stability studies Determine maximum likely level as: A + increase in degradation product at appropriate storage conditions. (Let this = B) YES YES NO NO ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE 1 Relevant batches are those from development, pilot and scale-up studies. 2 Refer to ICH Guideline on Impurities in New Drug Substances Definition: upper confidence limit = three times the standard deviation of batch analysis data Determine mean + upper confidence limit for the impurity (Let this = A)
  • 10.
    Does degradation occur during product manufacture? Estimatemaximum increase in degradation product at shelf life using data from relevant accelerated and long-term stability studies. (Let this = D) Determine maximum likely level as drug substance acceptance criterion2 . ((A or B) + C + D) Is maximum likely level greater than the qualified level? Estimate maximum increase in degradation product during manufacture from relevant batches1 . (Let this = C) Acceptance criterion = maximum likely level. Acceptance criterion = qualified level or establish new qualified level3 or new storage conditions or reduce shelf life. NO NO YES YES ESTABLISHING ACCEPTANCE CRITERION FOR A DEGRADATION PRODUCT IN A NEW DRUG PRODUCT 1 Relevant batches are those from development, pilot and scale-up studies. 2 Refer to Decision Tree 1 for information regarding A and B. 3 Refer to ICH Guideline on Impurities in New Drug Products.
  • 11.
    Is the drugproduct a solid dosage form or liquid containing undissolved drug substance? No drug substance particle size acceptance criterion required for solution dosage forms. 1. Is the particle size critical to dissolution, solubility, or bioavailability? 2. Is the particle size critical to drug product processability? 3. Is the particle size critical to drug product stability? 4. Is the particle size critical to drug product content uniformity? 5. Is particle size critical for maintaining product appearance? Set Acceptance Criterion No Acceptance Criterion Required If YES to any If NO to all NO YES SETTING ACCEPTANCE CRITERIA FOR DRUG SUBSTANCE PARTICLE SIZE DISTRIBUTION
  • 12.
    INVESTIGATING THE NEEDTO SET ACCEPTANCE CRITERIA FOR POLYMORPHISM IN DRUG SUBSTANCES AND DRUG PRODUCTS Drug Substance 1. 2. NO YES Conduct polymorphism screen on drug substance. No further action Can different polymorphs be formed? GO TO Characterize the forms: e.g., - X-ray Powder Diffraction - DSC / Thermoanalysis - Microscopy - Spectroscopy
  • 13.
    INVESTIGATING THE NEEDTO SET ACCEPTANCE CRITERIA FOR POLYMORPHISM IN DRUG SUBSTANCES AND DRUG PRODUCTS 2. 3.GO TO NO NO YES Do the forms have different properties? (solubility, stability, melting point) Is drug product safety, performance or efficacy affected? No further test or acceptance criterion for drug substance YES Set acceptance criterion for polymorph content in drug substance
  • 14.
    INVESTIGATING THE NEEDTO SET ACCEPTANCE CRITERIA FOR POLYMORPHISM IN DRUG SUBSTANCES AND DRUG PRODUCTS 3. YES NO NO YES Does drug product performance testing provide adequate control if polymorph ratio changes (e.g., dissolution)? Establish acceptance criteria for the relevant performance test(s). Monitor polymorph form during stability of drug product. No need to set acceptance criteria for polymorph change in drug product. Does a change occur which could affect safety or efficacy? Establish acceptance criteria which are consistent with safety and/or efficacy. Drug Product - Solid Dosage Form or Liquid Containing Undissolved Drug Substance Undertake the following processes only if technically possible to measure polymorph content in the drug product.
  • 15.
    ESTABLISHING IDENTITY, ASSAYAND ENANTIOMERIC IMPURITY PROCEDURES FOR CHIRAL NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS CONTAINING CHIRAL DRUG SUBSTANCES YES AND RACEMIC Consider the need for verifying chiral identity in drug substance release and/or acceptance testing. Is the new drug substance chiral1 ? Chiral identity, assay and impurity procedures are not needed. YES AND ONE ENANTIOMER Needed for drug substance specification:2 -chiral identity3 -chiral assay4 -enantiomeric impurity5 Needed for drug product specification6 : -chiral assay4 -enantiomeric impurity5 NO 1 Chiral substances of natural origin are not addressed in this Guideline. 2 As with other impurities arising in and from raw materials used in drug substance synthesis, control of chiral quality could be established alternatively by applying limits to appropriate starting materials or intermediates when justified from developmental studies. This essentially will be the case when there are multiple chiral centers (e.g., three or more), or when control at a step prior to production of the final drug substance is desirable. 3 A chiral assay or an enantiomeric impurity procedure may be acceptable in lieu of a chiral identity procedure. 4 An achiral assay combined with a method for controlling the opposite enantiomer is acceptable in lieu of a chiral assay. 5 The level of the opposite enantiomer of the drug substance may be derived from chiral assay data or from a separate procedure. 6 Stereospecific testing of drug product may not be necessary if racemization has been demonstrated to be insignificant during drug product manufacture and during storage of the finished dosage form.
  • 16.
    MICROBIOLOGICAL QUALITY ATTRIBUTESOF DRUGSMICROBIOLOGICAL QUALITY ATTRIBUTES OF DRUGS SUBSTANCE AND EXCIPIENTSSUBSTANCE AND EXCIPIENTS Is the drug substances/excipient Capable of supporting microbial Growth or viability Is the drug substances/excipient Sterile? Does drug substances/excipient Synthesis/processing involve Steps which inherently Reduce microorganisms? Establish microbial limit acceptance Criteria As per the harmonized pharmacopoeial monograph Are monitoring Microorganism/indicator levels Consistently below acceptance criteria Levels? Test lots on a skip-lot basis for Microbial limits and freedom from Compendial indicator organisms. Test each lot for microbial limits and freedom from compendial indicator organisms. Provide supporting data. Microbial Limits acceptance criteria and testing May not be necessary No further microbial limits testing or Acceptance criteria are necessary Establish microbial limit acceptance criteria As per the harmonized pharmacopeial monograph Does scientific evidence demonstrate that Reducation steps result in microorganism levels <acceptance criteria limits (and the absence of Compendial indicator organisms) In the drug substance/excipient? Provide supporting data. Microbial limits acceptace Criteria and testing May not be necessary YES YES YES YES YES NO NO NO NO NO
  • 17.
    1 . What type ofdrug release acceptance criteria are appropriate? Is the dosage form designed to produce modified release? YES Establish drug release acceptance criteria. Extended release: multiple time points Delayed release: two stages, parallel or sequential Is drug solubility at 37 ± 0.5°C high throughout the physiological pH range? (Dose/ solubility < 250 mL (pH 1.2 - 6.8)) NO Continued on next page. Generally single-point dissolution acceptance criteria with a lower limit are acceptable. Is dosage form dissolution rapid? (Dissolution > 80% in 15 minutes at pH 1.2, 4.0, and 6.8) Has a relationship been determined between disintegration and dissolution? Generally disintegration acceptance criteria with an upper time limit are acceptable. YES NO YES YES NO NO SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION
  • 18.
    2. What specifictest conditions and acceptance criteria are appropriate? [immediate release] Does dissolution significantly affect bioavailability? (e.g., have relevant developmental batches exhibited unacceptable bioavailability?) Attempt to develop test conditions and acceptance criteria which can distinguish batches with unacceptable bioavailability. YES NO YES NO YES NO Do changes in formulation or manufacturing variables affect dissolution? (Use appropriate ranges. Evaluate dissolution within pH 1.2 - 6.8) Are these changes controlled by another procedure and acceptance criterion? Adopt appropriate test conditions and acceptance criteria without regard to discriminating power, to pass clinically acceptable batches. Adopt test conditions and acceptance criteria which can distinguish these changes. Generally, single point acceptance criteria are acceptable. SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION
  • 19.
    3. YES NO NO YES YES NO YES NO Are bioavailability data availablefor batches with different drug release rates? Is drug release independent of in vitro test conditions? Can an in vitro / in vivo relationship be established? (Modify in vitro test conditions if appropriate.) Use all available stability, clinical, and bioavailability data to establish appropriate acceptance ranges. Use the in vitro / in vivo correlation, along with appropriate batch data, to establish acceptance ranges. Are acceptance ranges >20% of the labeled content? Provide appropriate bioavailability data to validate the acceptance ranges. Finalize acceptance ranges. SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION What are appropriate acceptance ranges? [extended release]
  • 20.
    MICROBIOLOGICAL ATTRIBUTES OFNON-STERILEMICROBIOLOGICAL ATTRIBUTES OF NON-STERILE DRUGS PRODUCTSDRUGS PRODUCTS Does the drug product contain Antimicrobial preservatives or possess Inherent antimicrobial activity Is the drug product a dry dosage form (e.g. solid oral or dry powder)? Does scientific evidence demonstrate Growth inhibitory properties of the Drug product? Microbial limits acceptance criteria and testing May not be necessary Establish preservative chemical acceptance criteria and Perform preservative effectiveness validation of product Containing less than or equal to the minimum specifie Preservative concentration, or demonstrate the inherent Antimicrobial activity of the drug product. Establish microbial limit acceptance criteria As per the harmonized pharmacopoeia Monograph. Perform microbial limits testing on a Lot-by-lot basis. Do production lots consistently meet Microbial limits acceptance criteria? Perform skip-lot testing for microbial Limits, or provide scientific justification for no routine microbial limits testing. No No No No YES YES YES YES
  • 21.
  • 22.
    ICH Harmonised TripartiteGuidelineICH Harmonised Tripartite Guideline • Stability Testing of New Drug Substances and Products • Stability Testing: Photostability Testing of New Drug Substances and Products • Stability Testing for New Dosage Forms • Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products • Evaluation for Stability Data • Stability Data Package for Registration Applications in Climatic Zones III and IV • Validation of Analytical Procedures: Text and Methodology • Impurities In New Drug Substances
  • 23.
    ICH Harmonised TripartiteGuidelineICH Harmonised Tripartite Guideline • Impurities in New Drug Products • Impurities: Guideline for Residual Solvents • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Microbiological Examination of Non-Sterile Products: Microbial Enumerations Tests • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Microbiological Examination of Non-Sterile Products: Test for Specified Micro-Organisms
  • 24.
    ICH Harmonised TripartiteGuidelineICH Harmonised Tripartite Guideline • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Residue on Ignition/Sulphated Ash • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Extractable Volume of Parenteral Preparations
  • 25.
    ICH Harmonised TripartiteGuidelineICH Harmonised Tripartite Guideline • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Particulate Contamination: Sub-Visible Particles • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Disintegration • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Uniformity of Dosage Units • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Region on Dissolution Test
  • 26.
    ICH Harmonised TripartiteGuidelineICH Harmonised Tripartite Guideline • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Sterility Test • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions onTablet Friability • Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Polyacrylamide Gel Electrophoresis • Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin
  • 27.
    ICH Harmonised TripartiteGuidelineICH Harmonised Tripartite Guideline • Quality of Biotechnological Products: Analysis of the Expression Construct in Cells used for Production of r-DNA Derived Protein Products • Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products • Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products • Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process • Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
  • 28.
    ICH Harmonised TripartiteGuidelineICH Harmonised Tripartite Guideline • Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products • Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients • Pharmaceutical Development • Quality Risk Management • Pharmaceutical Quality System • Quality Implementation Working Group
  • 29.
    Quality Assurance (QA)Management Procedure
  • 30.
    How to writeStandard OperatingHow to write Standard Operating ProcedureProcedure • SOP describes standard SOP format that you can use immediately for your quality procedure. • SOP has instructions on how to write a formal operating procedure for your systems which your people can follow everyday.
  • 31.
    All Documents-Classifications,All Documents-Classifications, Definitionand Approval MatrixDefinition and Approval Matrix • In this SOP you will find all type of quality and Technical/Master file documents to build up a good quality management system for your manufacturing sites, definition of documents, their classification, approval requirements and retention requirements. • This procedure has schematic diagrams for your understanding of how different types of documents are prepared and stored in a typical documentation.
  • 32.
    Quality Documentation ManagementQualityDocumentation Management and Change Controland Change Control • This SOP describes how to generate new quality documents or change control of existing documents, review of quality documents, satellite file management, role of document author, approver, document control officer and satellite file administrator. • In this SOP you will also find numbering systems of different quality documents like audit files, SOP’s, forms, manuals, training files, QA agreements, project files etc and their effective archiving system.
  • 33.
    Documentation Rule forGMPDocumentation Rule for GMP DocumentsDocuments • This SOP describes the principles to be followed in GMP documents, entry of data and information, signature requirements and correction technique of incorrectly entered data or information.
  • 34.
    Quality Documentation-Control,Quality Documentation-Control, Trackingand DistributionTracking and Distribution • In this SOP you will find mainly the role of document control officer during the initiation, creation, circulation and approval of new quality related documents. • It also describes the procedure of modification and review of existing document using a documentation database. • Management of existing and superseded documents is also a art of this procedure. • You will see all the forms referred during the instruction are attached at the end of the procedure.
  • 35.
    Preparation, Maintenance andPreparation,Maintenance and Change Control of Master DocumentsChange Control of Master Documents • This SOP particularly focused on the management of master file documents like specifications, control methods, raw materials, finished goods and packaging specification and test reports, formulation, stability files etc required to generate during the product registration in the market. • This SOP gives instruction on their creation, change control, numbering system, approval requirements and maintenance in a simple master file database. • You will see all the forms referred during the instruction are attached at the end of the procedure.
  • 36.
    Deviation Report SystemDeviationReport System • It is a regulatory requirement to capture all sorts of deviations evolves in your systems in order to maintain the continuous improvement to your processes and systems. • This SOP describes how to categorize the deviations between production, audit, quality improvements, technical deviations, customer complaints and environmental, health and safety deviations. • It describes the management responsibilities of initiating deviation, capture data, analysis, investigation, determination of assignable causes, generation of management report and initiatives to be taken on corrective and preventative actions.
  • 37.
    Shelf Life ofProductShelf Life of Product • This simple SOP describes the meaning of shelf life and provides on how to interpret shelf lives and storage conditions for your raw materials from the Certificate of Analysis, determining expiry date for your finished products by use of raw material date of manufacturing and their shelf lives.
  • 38.
    Vendor Selection andEvaluationVendor Selection and Evaluation • This SOP describes the procedure to be followed during the vendor assessment and vendor evaluation for purchasing of raw materials, critical and non critical packaging components, laboratory supplies, engineering supplies and imported finished goods from the vendor. • These instructions are essential for approving prospective vendor.
  • 39.
    Vendor CertificationVendor Certification •This procedure aim to describe the process by which a vendor may be certified to supply materials or services. • This procedure applies to vendors that supply a material or service to be used at any stage of manufacture by operations. • Here you will get the roles of each department in the process to certify an approved vendor.
  • 40.
    Product Complaint ProcedureProductComplaint Procedure • This procedure covers the receipt, logging, evaluation, investigation and reporting system of all complaints received from customers for the marketed products. • This SOP contains step by step instruction to be followed in the customer complaint management like numbering of complaint, registration, evaluation of complaints, determination of assignable cause for the complaint deviation, implementation of corrective and preventive actions, trending of complaints and handling of counterfeit products.
  • 41.
    Annual Product ReviewAnnualProduct Review • This procedure provides a guideline to annual product review which is required to be performed for each product produced for the commercial market to evaluate data, trends and to identify any preventative or corrective action that would lead to product quality improvements and report them to management.
  • 42.
    Rework ProcedureRework Procedure •This SOP contains the step by step instruction to be followed when the rework of an in-process or completed finished good is required. • This SOP covers the reworks of in-process manufactured goods where new batch number is introduced for the reworked part and rework of manufactured finished good keeping the same batch number. • This SOP also describes how to create rework protocols for each individual case.
  • 43.
    Authorized PersonAuthorized Person •This simple procedure describes the accreditation, accountabilities and responsibilities of an Authorized person, responsible for release of finished goods for sale.
  • 44.
    Product Identification andProductIdentification and TraceabilityTraceability • The purpose of this SOP is to define the method used for the identification of all contributing materials that could affect product quality and to ensure their full traceability. • Here you will find instruction on all the records and documents used for the identification and traceability of incoming raw materials and out going finished goods.
  • 45.
    AuditsAudits • This SOPdescribes the process of planning, performing, reporting and follow-up of different audits for your systems like Internal Quality audit, Vendor audit, Environmental Health and Safety (EHS) audit, EHS workplace inspection, Housekeeping audit. • This SOP also describes the process to be followed by manufacturing personnel during an audit from a Regulatory authority.
  • 46.
    Example-Checklist for BatchDocumentationExample-Checklist for Batch Documentation • This SOP describes the identification of all documentation relevant to a production process in the form of “Batch Documentation Checklists” and to ensure their collection by completion of the checklists by Authorized Persons. • This procedure is based on an example of tablet packaging process described in the ‘Manufacturing’ category.
  • 47.
    Evaluation of BatchDocumentationEvaluation of Batch Documentation and Release for Saleand Release for Sale • This procedure describes the process of collection, evaluation and record of batch related document generated during the production of a batch before an authorized person can release the batch for sale. • This procedure is based on an example of tablet packaging process described in the ‘Manufacturing’ category.
  • 48.
    GMP TrainingGMP Training •This SOP describes how to design and deliver GMP related training for your manufacturing staffs, training assessment design, recording of assessment and preparation of training reports.
  • 49.
    How to WriteTraining MaterialsHow to Write Training Materials • This simple SOP contains instructions on how to write training materials, identification of training requirements, available resources, preparation of training aid checklists for your manufacturing staffs.
  • 50.
    House Keeping AuditProcedureHouse Keeping Audit Procedure • This SOP describes the requirements, checklists and reporting procedure on housekeeping audits. • Individual checklist forms are attached at end of the procedure for different areas like process, laboratory, engineering stores, warehouses. • This procedure also describes the handling of non-compliance found during the housekeeping audits.
  • 51.
    Management and Controlof Contract WorkManagement and Control of Contract Work • The procedure describes the management and control of contract work provided by the contractors for packaging and finished products for your company as well as control of contract works done by your company on behalf of others.
  • 52.
    Criteria for Sourcingof RM, CriticalCriteria for Sourcing of RM, Critical Packaging Components and ImportedPackaging Components and Imported Finishing GoodsFinishing Goods • The purpose of this SOP is to describe the process for approval of an external vendor/manufacturer supplying products to your company. • It covers raw materials (including bulk products for subsidiaries and contract manufacturers), critical packaging components in contact with product and imported finished goods. • The SOP also references affiliated documentation detailing the scope of active materials used and the approved manufacturers of these materials.
  • 53.
    Quality Concern InvestigationQualityConcern Investigation ProcessProcess • This procedure contains instruction to be followed when conducting Investigations and to raise and assess Deviation Report when an investigation or incident Investigation occurs. • This procedure is to be used in conjunction with SOP, which covers the approval and follow-up activities associated with a Deviation Report. • Here you will find collection of information for an incident or a deviation, steps to be followed for a cross functional investigation, reporting and implementing of the outcomes of investigation.
  • 54.
  • 55.
    Retest Dating ofRaw MaterialsRetest Dating of Raw Materials • The purpose of this procedure is to describe how to run the expired stock report; to describe how to define the requirements for the retesting and assignment of storage period for active ingredients, excipients and raw materials; to instruct retesting procedure and to determine the status of a finished goods batch with a shorter shelf life.
  • 56.
    Calibration Policies forLaboratoryCalibration Policies for Laboratory InstrumentsInstruments • This SOP describes the calibration polices of laboratory instruments/equipments. • It describes labeling and security requirements of laboratory instruments/equipments. • This SOP also describes the investigational steps to be required in the case of failed calibration
  • 57.
    Archiving Laboratory DocumentationArchivingLaboratory Documentation • This procedure describes retention and disposal procedures of laboratory documentation, general laboratory documentation system that includes handling of rejected raw material and finished product reports, finished goods certificate of analysis, finished goods register, raw material certificate of analysis, register, trend cards, procedure for long term document retention.
  • 58.
    Management of ReferenceManagementof Reference SubstancesSubstances • This SOP describes the ordering referencing, storing, coding, use and general register maintenance of primary and impurity reference substances, primary reagent reference solutions, secondary raw material reference substance, assay testing procedure of secondary raw material reference substance, use of secondary raw material reference substance in the laboratory routine analysis, determination of expiry date and re-test date of reference substances.
  • 59.
    Laboratory WorkbookLaboratory Workbook •This SOP describes types of laboratory workbooks, general and GMP requirements of using workbooks, analytical data entry in the workbook, formatting of laboratory workbooks for routine testing, experiments and trials, workbook retention policy, instruction on data entry for incomplete experiments and additional data.
  • 60.
    Creation of Certificateof AnalysisCreation of Certificate of Analysis • The purpose of this procedure is to define the content and format of a Certificate of Analysis (C/A) and Certificate of Manufacture (C/M) and to provide guidance for issuing a Certificate of Analysis or Certificate of Manufacture and to locate the appropriate data required for this task.
  • 61.
    Managing Analytical ReagentsManagingAnalytical Reagents • This procedure identifies the need for all analytical reagents and solutions prepared from the reagents, to have an assigned expiry date and storage conditions recorded on the label. • Here you will find the procedure for purchase and management of analytical reagents and laboratory prepared reagents.
  • 62.
    Laboratory Waste ManagementLaboratoryWaste Management • This simple procedure describes how to dispose off laboratory generated wastes of toxic, explosive, flammable, corrosive, oxidizing and biologically damaging natures.
  • 63.
    Retention Samples-LaboratoryRetention Samples-Laboratory •The purpose of this SOP is to describe the finished good and raw material sample retention procedures, products manufacture and/or received onsite and/or chemically tested by the laboratory.
  • 64.
    Laboratory Supplier ApprovalLaboratorySupplier Approval • In this simple SOP you will find the procedure for approving laboratory suppliers and criteria for the purchase of equipment, instrumentation, consumables, durables and glassware for the laboratory.
  • 65.
    Laboratory Results-Out ofSpecificationLaboratory Results-Out of Specification InvestigationInvestigation • This procedure describes the actions to be taken by an analyst in the event the result of a test does not conform to raw material/components or finished products specifications for physical and chemical tests. • An out of specification (OOS) result does not necessarily mean the batch under investigation fails and shall be rejected. • The OOS result shall be investigated and the findings of the investigation, including re-test results shall be interpreted to evaluate the batch and reach a decision regarding release or rejection.
  • 66.
    Raw Materials-Laboratory TestingRawMaterials-Laboratory Testing and Documentationand Documentation • This SOP describes the procedure for sampling, location, pre-testing, testing and documentation of all raw materials and components subject to test, out of specification results, microbiological tests and release procedure for passed raw materials and components.
  • 67.
    Finished Goods-Laboratory TestingandFinished Goods-Laboratory Testing and DocumentationDocumentation • This SOP describes the procedure for sampling, location, pre-testing, testing and documentation of all finished products subject to test, reagents and standards to be used for analysis, management of out of specification results, microbiological tests and release procedure for passed finished goods.
  • 68.
    Preparation and MaintenanceofPreparation and Maintenance of Stability Protocols (Pharmaceuticals)Stability Protocols (Pharmaceuticals) • This procedure describes the preparation and management of stability protocols for marketed products. • This procedure is applicable to all protocols for stability studies on commercial products. • The responsibility of the commercial Site stability manager for creating and maintaining protocols that are required for studies that came as a result of validation or process deviation.
  • 69.
    Stability and TrialTesting ProcedureStability and Trial Testing Procedure (Pharmaceuticals)(Pharmaceuticals) • To describes the steps necessary to ensure the effective control of stability and trial testing programs of new and existing products. • This procedure is focused on setting up of stability programs, testing, reporting, general sampling procedure for stability programs, data generation and analysis, annual maintenance of stability, new product stability procedure, procedure for in-house trials, reporting and interpretation of trials and conclusion of the trail program.
  • 70.
  • 71.